Protalix BioTherapeutics Q3 revenue, profit drop on varying client purchase patterns

Protalix BioTherapeutics

13/11/2025 11:58

Overview

Protalix Q3 2025 revenue decreases 1% year-over-year to $17.9 mln

Net income for Q3 2025 was $2.4 mln, down from $3.2 mln in Q3 2024

Outlook

Company plans to initiate phase 2 trial for PRX-115 later this year

Protalix expects significant R&D expenses as trials advance

Chiesi seeks re-examination of Elfabrio dosing regimen in EU

Result Drivers

PARTNER PURCHASE VARIABILITY - Revenue decline attributed to varying purchase patterns by Chiesi, Pfizer, and Fiocruz

R&D EXPENSES - Increased R&D expenses due to preparations for phase 2 trial of PRX-115

ENZYME THERAPIES - Continued commercial success of enzyme replacement therapies supports R&D

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$17.90 mln
Q3 EPS
$0.03
Q3 Net Income
$2.36 mln
Q3 Operating Income
$2.13 mln
Q3 Pretax Profit
$2.24 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 3 three months ago

Press Release: ID:nPn7lchDHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)